A Study of Pegylated Liposomal Doxorubicin in Platinum-Refractory Epithelial Ovarian Cancer

Publisher： Karger

E-ISSN： 1423-0232|67|3-4|183-186

ISSN： 0030-2414

Source： Oncology, Vol.67, Iss.3-4, 2004-11, pp. : 183-186

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 243-249

Karger

Access to resources Recommend Favorite

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-05 ,pp. : 433-437

Karger

Access to resources Recommend Favorite

A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 463-469

Karger

Access to resources Recommend Favorite

Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

By  

Oncology, Vol. 76, Iss. 1, 2008-11 ,pp. : 49-54

Karger

Access to resources Recommend Favorite

Phase I Study of Gemcitabine and Liposomal Doxorubicin in Relapsed Ovarian Cancer

By  

Oncology, Vol. 62, Iss. 2, 2002-03 ,pp. : 110-114

Karger

Access to resources Recommend Favorite